Pencil Beam Scanning Carbon Ion Radiotherapy for Hepatocellular Carcinoma

References

• Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S94–S100. doi:10.1016/j.ijrobp.2009.06.092
   PubMed Web of Science ®Google Scholar
• Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31(13):1631–1639. doi:10.1200/JCO.2012.44.1659
   PubMed Web of Science ®Google Scholar
• Yu Y, Feng M. Radiotherapy for hepatocellular carcinoma. Semin Radiat Oncol. 2018;28(4):277–287. doi:10.1016/j.semradonc.2018.06.005
   PubMed Web of Science ®Google Scholar
• Kobeissi JM, Hilal L, Simone CB, et al. Proton therapy in the management of hepatocellular carcinoma. Cancers. 2022;14(12). doi:10.3390/cancers14122900
   Web of Science ®Google Scholar
• Abousaida B, Seneviratne D, Hoppe BS, et al. Carbon ion radiotherapy in the management of hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:1169–1179. doi:10.2147/JHC.S292516
   PubMed Web of Science ®Google Scholar
• Byun HK, Kim C, Seong J. Carbon ion radiotherapy in the treatment of hepatocellular carcinoma. Clin Mol Hepatol. 2023;29(4):945–957. doi:10.3350/cmh.2023.0217
   PubMed Web of Science ®Google Scholar
• Apisarnthanarax S, Bowen SR, Combs SE. Proton beam therapy and carbon ion radiotherapy for hepatocellular carcinoma. Semin Radiat Oncol. 2018;28(4):309–320. doi:10.1016/j.semradonc.2018.06.008
   PubMed Web of Science ®Google Scholar
• Durante M, Loeffler JS. Charged particles in radiation oncology. Nat Rev Clin Oncol. 2010;7(1):37–43. doi:10.1038/nrclinonc.2009.183
   PubMed Web of Science ®Google Scholar
• Tinganelli W, Durante M. Carbon ion radiobiology. Cancers. 2020;12(10). doi:10.3390/cancers12103022
   PubMed Web of Science ®Google Scholar
• Shibuya K, Ohno T, Terashima K, et al. Short-course carbon-ion radiotherapy for hepatocellular carcinoma: a multi-institutional retrospective study. Liver Int. 2018;38(12):2239–2247. doi:10.1111/liv.13969
   PubMed Web of Science ®Google Scholar
• Shibuya K, Katoh H, Koyama Y, et al. Efficacy and safety of 4 fractions of carbon-ion radiation therapy for hepatocellular carcinoma: a prospective study. Liver Cancer. 2022;11(1):61–74. doi:10.1159/000520277
   PubMedGoogle Scholar
• Habermehl D, Debus J, Ganten T, et al. Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma – feasibility and clinical response. Radiat Oncol. 2013;8(1):59. doi:10.1186/1748-717X-8-59
   PubMed Web of Science ®Google Scholar
• Noda K. Beam delivery method for carbon-ion radiotherapy with the heavy-ion medical accelerator in Chiba. Int J Part Ther. 2016;2(4):481–489. doi:10.14338/IJPT-15-00041.1
   PubMedGoogle Scholar
• Chang JY, Zhang X, Knopf A, et al. Consensus guidelines for implementing pencil-beam scanning proton therapy for thoracic malignancies on behalf of the PTCOG Thoracic and Lymphoma Subcommittee. Int J Radiat Oncol Biol Phys. 2017;99(1):41–50. doi:10.1016/j.ijrobp.2017.05.014
   PubMed Web of Science ®Google Scholar
• Karger CP, Peschke P. RBE and related modeling in carbon-ion therapy. Phys Med Biol. 2017;63(1):01TR02. doi:10.1088/1361-6560/aa9102
   PubMed Web of Science ®Google Scholar
• Ye SL. Expert consensus on standardization of the management of primary liver cancer. Zhonghua Gan Zang Bing Za Zhi. 2009;17(6):403–410.
   PubMedGoogle Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. doi:10.1055/s-0030-1247132
   PubMed Web of Science ®Google Scholar
• Hong Z, Zhang W, Cai X, et al. Carbon ion radiotherapy with pencil beam scanning for hepatocellular carcinoma: long-term outcomes from a phase I trial. Cancer Sci. 2023;114(3):976–983. doi:10.1111/cas.15633
   PubMed Web of Science ®Google Scholar
• Kato H, Tsujii H, Miyamoto T, et al. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys. 2004;59(5):1468–1476. doi:10.1016/j.ijrobp.2004.01.032
   PubMed Web of Science ®Google Scholar
• Kasuya G, Kato H, Yasuda S, et al. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: combined analyses of 2 prospective trials. Cancer. 2017;123(20):3955–3965. doi:10.1002/cncr.30816
   PubMed Web of Science ®Google Scholar
• Yasuda S, Kato H, Imada H, et al. Long-term results of high-dose 2-fraction carbon ion radiation therapy for hepatocellular carcinoma. Adv Radiat Oncol. 2020;5(2):196–203. doi:10.1016/j.adro.2019.09.007
   PubMedGoogle Scholar
• Kim N, Cheng J, Huang WY, et al. Dose-response relationship in stereotactic body radiation therapy for hepatocellular carcinoma: a pooled analysis of an Asian Liver Radiation Therapy Group Study. Int J Radiat Oncol Biol Phys. 2021;109(2):464–473. doi:10.1016/j.ijrobp.2020.09.038
   PubMed Web of Science ®Google Scholar
• Komatsu S, Fukumoto T, Demizu Y, et al. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer. 2011;117(21):4890–4904. doi:10.1002/cncr.26134
   PubMed Web of Science ®Google Scholar
• Wakatsuki M, Makishima H, Mori Y, et al. Clinical outcomes of carbon-ion radiotherapy for large-sized (≥4cm) hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2023;117(2S):e348. doi:10.1016/j.ijrobp.2023.06.2418
   PubMedGoogle Scholar
• Feng M, Suresh K, Schipper MJ, et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a Phase 2 Clinical Trial. JAMA Oncol. 2018;4(1):40–47. doi:10.1001/jamaoncol.2017.2303
   PubMed Web of Science ®Google Scholar
• Durand-Labrunie J, Baumann AS, Ayav A, et al. Curative irradiation treatment of hepatocellular carcinoma: a multicenter Phase 2 trial. Int J Radiat Oncol Biol Phys. 2020;107(1):116–125. doi:10.1016/j.ijrobp.2019.12.004
   PubMed Web of Science ®Google Scholar
• Mizumoto M, Okumura T, Hashimoto T, et al. Evaluation of liver function after proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012;82(3):e529–e535. doi:10.1016/j.ijrobp.2011.05.056
   PubMed Web of Science ®Google Scholar
• Hsieh CE, Venkatesulu BP, Lee CH, et al. Predictors of radiation-induced liver disease in eastern and western patients with hepatocellular carcinoma undergoing proton beam therapy. Int J Radiat Oncol Biol Phys. 2019;105(1):73–86. doi:10.1016/j.ijrobp.2019.02.032
   PubMed Web of Science ®Google Scholar
• Osmundson EC, Wu Y, Luxton G, et al. Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract. Int J Radiat Oncol Biol Phys. 2015;91(5):986–994. doi:10.1016/j.ijrobp.2014.11.028
   PubMed Web of Science ®Google Scholar
• Chiba T, Tokuuye K, Matsuzaki Y, et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res. 2005;11(10):3799–3805. doi:10.1158/1078-0432.CCR-04-1350
   PubMed Web of Science ®Google Scholar
• Mizumoto M, Tokuuye K, Sugahara S, et al. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int J Radiat Oncol Biol Phys. 2008;71(2):462–467. doi:10.1016/j.ijrobp.2007.09.056
   PubMed Web of Science ®Google Scholar
• Yoo GS, Yu JI, Park HC, et al. Do biliary complications after proton beam therapy for perihilar hepatocellular carcinoma matter? Cancers. 2020;12(9). doi:10.3390/cancers12092395
   Web of Science ®Google Scholar
• Yu JI, Park HC, Lim DH, et al. Do biliary complications after hypofractionated radiation therapy in hepatocellular carcinoma matter? Cancer Res Treat. 2016;48(2):574–582. doi:10.4143/crt.2015.076
   PubMed Web of Science ®Google Scholar
• Kanemoto A, Mizumoto M, Okumura T, et al. Dose-volume histogram analysis for risk factors of radiation-induced rib fracture after hypofractionated proton beam therapy for hepatocellular carcinoma. Acta Oncol. 2013;52(3):538–544. doi:10.3109/0284186X.2012.718094
   PubMed Web of Science ®Google Scholar
• Yeung R, Bowen SR, Chapman TR, et al. Chest wall toxicity after hypofractionated proton beam therapy for liver malignancies. Pract Radiat Oncol. 2018;8(4):287–293. doi:10.1016/j.prro.2017.12.007
   PubMed Web of Science ®Google Scholar
• Li H, Dong L, Bert C, et al. AAPM Task Group Report 290: respiratory motion management for particle therapy. Med Phys. 2022;49(4):e50–e81. doi:10.1002/mp.15470
   PubMed Web of Science ®Google Scholar
• Kirilova A, Lockwood G, Choi P, et al. Three-dimensional motion of liver tumors using cine-magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2008;71(4):1189–1195. doi:10.1016/j.ijrobp.2007.11.026
   PubMed Web of Science ®Google Scholar
• Park JC, Park SH, Kim JH, et al. Liver motion during cone beam computed tomography guided stereotactic body radiation therapy. Med Phys. 2012;39(10):6431–6442. doi:10.1118/1.4754658
   PubMed Web of Science ®Google Scholar
• Hsi W, Huang Z, Wang W, et al. SU-E-T-281: dose measurements of modulated spot-scanning particle beams with beam-gating of respiratory-phase. Med Phys. 2015;42(6):3397. doi:10.1118/1.4924643
   Web of Science ®Google Scholar
• Hiroshima Y, Wakatsuki M, Kaneko T, et al. Clinical impact of carbon‐ion radiotherapy on hepatocellular carcinoma with Child‐Pugh B cirrhosis. Cancer Med. 2023;12(13):14004–14014. doi:10.1002/cam4.6046
   PubMed Web of Science ®Google Scholar